Gracell Financial Statements From 2010 to 2024
| GRCLDelisted Stock | USD 4.02 0.26 6.07% |
Check Gracell Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gracell Biotechnologies' main balance sheet or income statement drivers, such as , as well as many indicators such as . Gracell financial statements analysis is a perfect complement when working with Gracell Biotechnologies Valuation or Volatility modules.
Gracell |
Gracell Biotechnologies Company Current Valuation Analysis
Gracell Biotechnologies' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Gracell Biotechnologies Current Valuation | 3.32 B |
Most of Gracell Biotechnologies' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gracell Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Gracell Biotechnologies has a Current Valuation of 3.32 B. This is 76.86% lower than that of the Biotechnology sector and 28.44% lower than that of the Health Care industry. The current valuation for all United States stocks is 80.0% higher than that of the company.
Gracell Biotechnologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gracell Biotechnologies's current stock value. Our valuation model uses many indicators to compare Gracell Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gracell Biotechnologies competition to find correlations between indicators driving Gracell Biotechnologies's intrinsic value. More Info.Gracell Biotechnologies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Gracell Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Gracell Biotechnologies Financial Statements
Gracell Biotechnologies investors utilize fundamental indicators, such as revenue or net income, to predict how Gracell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the Peoples Republic of China. The company was founded in 2017 and is headquartered in Suzhou, China. Gracell Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 348 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |